Key Dates

Related Announcements

RFA-RM-22-016 - Platform Clinical Trials of Genome Editors in Multiple Diseases (UG3/UH3, Clinical Trial Required)

Issued by

Office of Strategic Coordination (Common Fund)

Purpose

The purpose of this Notice is to inform applicants of changes to the Application Due Date and and Expiration Date for RFA-RM-22-016 "Platform Clinical Trials of Genome Editors in Multiple Diseases (UG3/UH3, Clinical Trial Required)". The following section has been modified to reflect changes to the due date for new applications:

Currently Dates:

Key Dates

Open Date (Earliest Submission Date)

June 17, 2022

Letter of Intent Due Date(s)

June 17, 2022

All applications are due by 5:00 PM local time of applicant organization.

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Expiration Date

July 20, 2022

Modified to Read (changes shown in bold italics)

Key Dates

Open Date (Earliest Submission Date)

June 17, 2022

Letter of Intent Due Date(s)

October 7, 2022

All applications are due by 5:00 PM local time of applicant organization.

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Expiration Date

November 11, 2022

All other aspects of this FOA remain unchanged.

Inquiries

Please direct all inquiries to:

Philip J. ("Pj") Brooks, Ph.D.
National Center for Advancing Translational Sciences (NCATS)
Telephone: 301-443-0513
Email: [email protected]